LEU Stock Rallies As HALEU Backlog And Guidance Jump

Centrus Energy Corp. gained on news of expanded nuclear fuel contracts, and stocks have been trading up by 9.17 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading LEU

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Q2 2026 revenue hit $176.1M, up 14% year over year and well ahead of the $149.8M consensus, with adjusted EPS of $1.77 crushing the $0.92 estimate despite lower GAAP net income.
FY26 revenue guidance of $450M–$500M edges past the $459.23M street view, showing management’s confidence in Centrus Energy’s growth path.
A long-term X-energy deal for LEU and HALEU, with prepayments, helps fund LEU’s American enrichment buildout while deepening its already large, largely locked-in backlog.
Total backlog expanded to about $4.5B, including $3.0B of contingent enrichment work and a $900M DOE HALEU award, reinforcing LEU’s role in a tight global enrichment market.
Street sentiment stays broadly constructive on LEU, with multiple firms trimming or lifting price targets but keeping Buy, Outperform, Neutral, or Equal Weight ratings in place.

Live Update At 16:47:18 EDT: On Tuesday, August 25, 2026 Centrus Energy Corp. stock [NYSE: LEU] is trending up by 9.17%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

LEU has been trading like a high-voltage momentum name. Over the last few weeks, Centrus Energy shares have repeatedly bounced between the mid-$170s and just under $200, with the latest close near $193. That puts LEU toward the top of its recent range and signals traders are willing to pay up for the story after the Q2 surprise.

On 2026/08/25, LEU opened near $176, dipped briefly, then marched higher through the afternoon, finishing close to the intraday high. The 5‑minute tape shows steady, stair-step buying rather than a single spike, the kind of controlled grind trend traders like to ride.

Fundamentally, Centrus Energy just printed Q2 revenue of $176.1M, up 14% year over year and ahead of expectations. GAAP net income was $16.8M, but adjusted net income climbed to $38.7M, showing the core business throwing off more cash as enrichment demand tightens. Margins are still modest, with EBIT margin under 7%, yet LEU is clearly gaining pricing power.

More Breaking News

Valuation is rich. A P/E above 90 and price-to-sales near 7.8 tell traders that Centrus Energy is priced as a growth and scarcity asset. With leverage elevated but liquidity strong, LEU trades like a high‑beta way to play the nuclear fuel cycle, not a sleepy utility proxy.

Why Traders Are Watching LEU Right Now

Traders are glued to LEU because Centrus Energy sits right at the pinch point of the nuclear fuel chain. It runs the only active U.S. facility licensed to produce high assay low enriched uranium, or HALEU, which advanced reactors need. When there is one main gatekeeper for a scarce product, price and contract momentum often follow.

The latest quarter confirmed that dynamic. LEU’s adjusted EPS of $1.77 more than doubled the $0.92 consensus, powered by $176.1M in revenue and higher enrichment pricing in a tight supply environment. At the same time, management kept leaning into growth. Centrus Energy is expanding centrifuge manufacturing, locking in suppliers, and ramping its plants in Piketon, Ohio and Oak Ridge, Tennessee, with a first new centrifuge targeted by year-end 2026.

The contract flow backing that capex is serious. LEU landed a $900M HALEU enrichment award from the U.S. Department of Energy and pushed its total backlog to about $4.5B, with $3.0B tied to contingent enrichment. Then came the X-energy deal: a long-term contract to supply both LEU and HALEU, plus prepayments that help fund the American Centrifuge Plant buildout and reduce balance-sheet risk.

Street coverage reflects strong fundamentals but debates valuation. Needham still calls LEU a Buy with a $262 target after a minor trim, while Evercore ISI keeps an Outperform even after cutting its target to $337. Barclays initiated at Equal Weight with a $207 target, and Roth and UBS nudged targets higher but stuck with Neutral. That mix tells traders LEU’s story is powerful, but expectations are high and policy risks, like the planned 2028 ban on Russian uranium imports, remain key catalysts to track.

Conclusion

For active traders, LEU is a textbook momentum story built on real numbers, not just hype. Centrus Energy has revenue growing double digits, a multi‑billion‑dollar backlog, and locked-in HALEU capacity that no other U.S. name can match right now. The Q2 beat, the $450M–$500M FY26 revenue guide, and the X-energy and DOE deals all add fuel to the narrative that LEU is becoming a central player in the advanced nuclear build-out.

But this is not a smooth, low-volatility ride. A P/E north of 90, margin compression from heavy growth spending, and policy uncertainty on Russian uranium imports create real downside risk if headlines turn. Short term, LEU’s intraday grind higher and tight daily ranges around $180–$195 show strong hands in control, yet any disappointment on contracts, funding, or construction milestones in Oak Ridge and Piketon can flip that script fast.

This is where the Tim Sykes-style mindset matters. As Tim likes to say, “Treat every hot stock like it’s guilty until it proves itself innocent — let the chart and the catalysts confirm your thesis, and always be ready to cut losses fast.” That dovetails with the process-driven approach many top day traders follow; as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” With Centrus Energy, that means respecting the trend, watching backlog and policy news like a hawk, and never confusing a strong story with a guaranteed outcome. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!